Precision at Scale: Optimizing Cell-Free DNA Manufacturing for Next-Generation mRNA Vaccines and Therapeutics

October 16, 2026 | 11:00 AM ET

What if the future of mRNA manufacturing is cell-free?

Traditional plasmid DNA production can create bottlenecks in scalability, consistency, and sequence stability. This webinar explores how 4basebio’s enzymatic, cell-free synthetic DNA platform is helping overcome those challenges with high-quality, ready-to-use DNA templates for mRNA and DNA therapeutics.

Learn how the technology reduces impurities, improves RNA quality, enables stable synthesis of long poly(A) sequences, and supports the next generation of mRNA therapies.

Watch to discover:

Why plasmid DNA may be holding back mRNA manufacturing
How cell-free DNA production improves template quality
New solutions for poly(A) tail stability at scale
The potential impact on future mRNA and personalized medicines

FILL THE FORM BELOW

First Name *

Last Name *

Company Street Address *

Company Suite/Office *

Company Postal/Zip Code *

Company City *

Company State *

Company Country *

By submitting this content request, I have legitimate interest in the content and agree that Cell & Gene, their partners, and the creators of any other content I have selected may contact me regarding news, products, and services that may be of interest to me.

YesNo

What would you like to learn?

What stage best describes your team’s most advanced mRNA or DNA program?

What are your team’s biggest challenges with DNA templates for RNA production? * (select all that apply)
DNA template lead times or supply availabilityTemplate purity and its impact on RNA qualitySequence stability, including long poly(A) sequencManufacturing scale-up and batch consistencyCost of DNA template productionTransitioning from research-grade to GMP materialNo current challenges / exploring optionsOther

When might your team evaluate a new DNA template technology or supplier?